MA Certificate Correction and Voluntary Withdrawal in Ethiopia

1. Key takeaways

Two post-authorization procedures for Ethiopian market authorization certificates are frequently overlooked: certificate correction and voluntary withdrawal. Under Section 12.2 of EFDA-GDL-046 (Fourth Edition), an applicant who requests correction of an issued MA certificate must do so within one month of the date the certificate was issued; requests made after one month will not be corrected. Under Section 12.4, where a device already placed on the market has actually left the market or the manufacturer has stopped production, the MA certificate ceases to be valid; the MA holder must notify EFDA of any action to suspend placement, withdraw the product, request withdrawal or not seek renewal, together with the reasons, and must specifically declare whether the action involves device quality or the protection of public health. Both procedures are time-sensitive in different ways, and both carry consequences that are easy to underestimate from a distance.

2. Legal basis

3. Expert insights

Insight 1: The one-month rule is a cut-off period, not a processing deadline.

Section 12.2 states that a correction request must be made within one month of the certificate issue date, and that no certificate will be corrected if the request is made more than one month after issuance. This is not a promise that the authority will finish within a month; it is a rule that the applicant loses the right to correction by letting the month lapse. A company that files the certificate away on receipt and discovers a misprinted product name or model half a year later has no route through this procedure. The practical response is to verify the certificate on the day it arrives and treat any error as urgent.

Insight 2: Correction and appeal are two different roads.

Section 12.2 also provides that applicants may request a review of, or lodge a complaint about, a decision through the complaint-handling procedure established by EFDA. Correction of printing or recording errors and appeal against an official decision are therefore two independent procedures, and the one-month cut-off of the former does not apply to the latter. Conflating the two leads companies with legitimate appeals to assume they are time-barred, or companies with mere typographical errors to initiate heavier complaint procedures unnecessarily.

Insight 3: The trigger for voluntary withdrawal is the actual state, not the intention.

Section 12.4 is triggered when a device approved for the market is actually no longer on the market or the manufacturer has stopped producing it; at that point the MA certificate ceases to be valid as a matter of course. This means that even if the company takes no action, the certificate has already lost its force, while the notification obligation exists independently and continues to bind. Silence does not preserve the certificate, and it does not discharge the duty to inform the authority of what happened and why.

Insight 4: Whether the action involves quality or public health is a mandatory question in the notification.

Section 12.4 requires the holder to specifically declare whether the action involves device quality or the protection of public health. This elevates withdrawal from an administrative formality to a risk-information declaration: once a declaration touches quality or public health, EFDA can take further market surveillance or vigilance measures on that basis. Leaving the field blank or answering vaguely is itself a compliance defect and invites follow-up questions the company may not be ready for.

Insight 5: Withdrawal and re-registration are mutually exclusive choices.

The withdrawal notification sits alongside the notification of non-renewal in Section 12.4; read with Section 12.1, a company choosing not to renew lets the certificate lapse at the end of the 5-year term, and any later re-entry to the market must proceed through a new application. The same re-entry cost applies after a withdrawal or after an expiry, so the decision to exit should weigh the realistic probability of returning.

4. Practical recommendations

1. Build a verify-on-receipt action: on the day the MA certificate arrives, check the holder name, product name, model, classification, UMDN code, manufacturer name and address, and validity period; if an error is found, file the correction request immediately and always within one month.
2. Preserve evidence of the issue date: run an internal 30-day countdown from the issue date printed on the certificate.
3. Separate correction from appeal: typographical and recording errors go through Section 12.2 correction; dissatisfaction with a review decision goes through the EFDA complaint-handling procedure.
4. Notify upon market exit: when a product actually leaves the market or production stops, proactively submit a withdrawal notification to EFDA stating the action and the reasons.
5. Put the quality / public-health question in writing: give a considered written answer rather than leaving it blank or ambiguous.
6. Choose withdrawal cautiously if a return is plausible: re-entry after withdrawal or after expiry follows a new application, with requirements and review duration identical to a first registration.

5. Verification checklist

• □ All certificate details were verified on the day the MA certificate was received
• □ If errors existed, the correction was requested within one month of issuance
• □ The distinction between the correction and appeal procedures has been confirmed
• □ A withdrawal notification was submitted to EFDA after market exit or production stop
• □ The notification states the action and the reasons
• □ The notification declares whether device quality or public health protection is involved
• □ The cost of re-entry through a new application has been assessed before withdrawal

Regulatory information verified as of October 29, 2026. The correction time limit and withdrawal notification obligations listed in this article are governed by the current text of Sections 12.2 and 12.4 of the fourth edition of EFDA-GDL-046; when the guideline is revised, the provisions must be re-checked.

Local resource in Ethiopia: GRZAN supports manufacturers from the Chinese mainland and overseas in engaging with the Ethiopian Food and Drug Authority (EFDA) on market authorization (MA), Certificate of Competence (CoC) and import permit applications, including local agent structuring and agency agreement review, SRA reliance pathway justification, UMDN coding and classification determination, technical documentation preparation, and the establishment of vigilance and post-market surveillance systems. Service capabilities cover product attribute determination and risk classification (non-IVD Class I–IV / IVD Class A–D), market authorization applications and re-registration, applicability assessment for the low-risk notification procedure, Essential Principles conformity reasoning, label and instruction-for-use localization in English, and vigilance reporting with field safety corrective action support. Contact: hito.lin@grzan.cn; website www.grzan.cn. For certificate correction, market-exit notifications and local authorized representative support in the Ethiopian market, GRZAN can also be reached at info@grzanglobal.com.